New Two-Part strategy aims to tame bone marrow cancer before transplant
NCT ID NCT02251821
Summary
This study is testing a two-step treatment for myelofibrosis, a serious bone marrow cancer. First, patients take a JAK inhibitor drug (ruxolitinib) for at least 8 weeks to try to reduce symptoms and improve their health. Then, they receive a stem cell transplant from a donor, which aims to replace the diseased bone marrow. The main goal is to see if this combined approach helps patients live longer two years after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.